Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162210 · ClinicalTrials.gov registry record · Phase 3
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase 3 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT04162210 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 325 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04162210, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
- DRUG Pom/dex (Pomalidomide plus low dose Dexamethasone)
Study Locations (20)
Other
- GSK Investigational Site - Bruges
- GSK Investigational Site - Brussels
- GSK Investigational Site - Brussels
- GSK Investigational Site - Edegem
- GSK Investigational Site - Kortrijk
Oregon
- GSK Investigational Site - Corvallis
- GSK Investigational Site - Eugene
Victoria
- GSK Investigational Site - Fitzroy
- GSK Investigational Site - Geelong
Arizona
- GSK Investigational Site - Tucson
Colorado
- GSK Investigational Site - Pueblo
Michigan
- GSK Investigational Site - Detroit
Nebraska
- GSK Investigational Site - Omaha
New York
- GSK Investigational Site - Clifton Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2027-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04162210
The ClinicalTrials.gov registry entry for NCT04162210 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (40% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Belantamab mafodotin is the first listed.
NCT04162210 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Oregon, Victoria.
Frequently Asked Questions
What is clinical trial NCT04162210 about?
NCT04162210 is a clinical study titled "Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)". This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will b...
What is the current status of trial NCT04162210?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2021-03-24. Estimated completion is 2027-03-11.
What conditions does trial NCT04162210 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04162210?
The interventions under investigation include: Belantamab mafodotin (DRUG), Pom/dex (Pomalidomide plus low dose Dexamethasone) (DRUG).
Who is sponsoring clinical trial NCT04162210?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04162210 being conducted?
This trial has 20 study locations across Arizona, Colorado, Michigan, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.